Tyrosine kinase inhibitors (TKIs) targeting ROS1 have therapeutic activity for these cancers, while some ALK TKIs such as repotrectinib are also used in the treatment of patients with ROS1 fusion due to the 70% homology between the kinase structural domains of ALK and ROS1 (1, 2). Here, ALK is linked to cancer.